Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 432 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: gonadotropin releasing hormone Clear all
Completed Phase 1 Interventional

Psychostimulant Abuse - Novel Treatment Approaches - 1

NCT00000325
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Gonadorelin
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 7, 2026, 4:06 AM EDT
Active, not recruiting Phase 2 Interventional

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

NCT00329043
View directory record Official record
Conditions
Prostate Cancer
Interventions
LHRH Agonist, Sunitinib Malate, Radical Prostatectomy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 7, 2026, 4:06 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

NCT05306340
View directory record Official record
Conditions
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Interventions
Giredestrant, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
55
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 4 Interventional Results available

MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population

NCT02554279
View directory record Official record
Conditions
Infertility
Interventions
menotropin, recombinant FSH
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
21 Years to 35 Years · Female only
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Scottsdale, Arizona • Tempe, Arizona • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 7, 2026, 4:06 AM EDT
Active, not recruiting Phase 4 Interventional

Roll-over Study to Allow Continued Access to Ribociclib

NCT05161195
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
16
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition

NCT01762943
View directory record Official record
Conditions
Postpartum Depression
Interventions
Leuprolide Acetate, Micronized estradiol, Progesterone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
22 Years to 50 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 7, 2026, 4:06 AM EDT
Not listed Phase 3 Interventional

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

NCT00458458
View directory record Official record
Conditions
Endometriosis, Dysmenorrhea, Dyspareunia
Interventions
Norethindrone Acetate (NA), GnRH Agonist (Lupron Depot)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

NCT00003394
View directory record Official record
Conditions
Prostate Cancer
Interventions
carboplatin, endocrine-modulating drug therapy, estramustine phosphate sodium, goserelin acetate, leuprolide acetate, paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 7, 2026, 4:06 AM EDT
Terminated Phase 3 Interventional Results available

Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer

NCT00429403
View directory record Official record
Conditions
Breast Cancer
Interventions
Goserelin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 46 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

NCT00669162
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Radiation Therapy, Casodex and Zoladex (or Lupron)
Drug · Radiation
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

NCT04648969
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
kisspeptin 112-121, GnRH
Drug
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

NCT03695237
View directory record Official record
Conditions
Central Precocious Puberty (CPP)
Interventions
Leuprolide Acetate (LA)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 11 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Long Beach, California • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 7, 2026, 4:06 AM EDT
Suspended Not applicable Interventional

Insulin Sensitivity in Men With the Metabolic Syndrome

NCT00433173
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test
Procedure · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years to 75 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

NCT03298087
View directory record Official record
Conditions
Newly Diagnosed Oligometastatic Prostate Cancer
Interventions
radical prostatectomy, stereotactic body radiotherapy, Leuprolide, apalutamide, abiraterone
Procedure · Radiation · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Long Beach, California • West Los Angeles, California • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 7, 2026, 4:06 AM EDT
Recruiting Phase 2 Interventional

Kisspeptin Administration Subcutaneously to Patients With IHH

NCT05896293
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
kisspeptin 112-121, leuprolide acetate
Drug
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 1Phase 2 Interventional

Endometriosis : Traditional Medicine vs Hormone Therapy

NCT00034047
View directory record Official record
Conditions
Endometriosis, Pelvic Pain
Interventions
Acupuncture, Chinese Products, Nafarelin
Procedure · Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 25, 2008 · Synced Oct 7, 2026, 4:06 AM EDT
Withdrawn Phase 2 Interventional

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

NCT06060587
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, ADT, Abiraterone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Not applicable Interventional

CaREFREE Study (Calorie Restriction, Environment and Fitness: Reproductive Effects Evaluation Study)

NCT02858336
View directory record Official record
Conditions
Hormones
Interventions
NEA, DEA
Behavioral
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 28 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)

NCT02057939
View directory record Official record
Conditions
Prostate Cancer
Interventions
enzalutamide, Androgen Deprivation, Radiation Therapy
Drug · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
New Brunswick, New Jersey • Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 7, 2026, 4:06 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

NCT04484818
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Darolutamide, Goserelin Acetate, Leuprolide Acetate, Placebo Administration, Quality-of-Life Assessment, Triptorelin
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
115
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 88 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 7, 2026, 4:06 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Endometrial Luteal Phase Characteristics and Luteal Phase Support in Controlled Ovarian Stimulation Protocols With GnRH Antagonists:Focusing on MicroRNA

NCT01510054
View directory record Official record
Conditions
Controlled Ovarian Stimulation
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 31 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2014
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 7, 2026, 4:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Androgen Deprivation Therapy on Cardiovascular Function in Prostate Cancer

NCT03275181
View directory record Official record
Conditions
Prostate Cancer
Interventions
Transthoracic Echocardiography, Arterial blood pressure, Submaximal Exercise
Diagnostic Test
Lead sponsor
Kansas State University
Other
Eligibility
21 Years to 80 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

NCT02278185
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Enzalutamide, leuprolide acetate, goserelin acetate, histrelin acetate, triptorelin, degarelix
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
Aurora, Colorado • Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 7, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

NCT01088529
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone Acetate, Prednisone, LHRHa
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 7, 2026, 4:06 AM EDT